Back to Search
Start Over
Patient access to rheumatoid arthritis treatments.
- Source :
-
The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2008 Jan; Vol. 8 Suppl 2, pp. S35-8. - Publication Year :
- 2008
-
Abstract
- This paper is an introduction to the study "The Burden of Rheumatoid Arthritis and Patient Access to Treatment". The objective of the study is to compare patient access to new drugs in Europe, North America and a selection of other countries, and to analyse the determinants of differences between countries, as basis for a discussion on how patients' access to new and effective treatments can be improved. There were few treatments available that could affect the progression of the disease prior to the introduction of the first TNF inhibitors in the late 1990s. Since the cost per patient treated with these biological drugs is high compared to previously available treatments, reimbursement through private and public insurance is an important determinant for access to treatment.
- Subjects :
- Arthritis, Rheumatoid economics
Disease Progression
Drug Costs
Europe
Humans
Insurance, Health, Reimbursement
North America
Sweden
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid drug therapy
Health Services Accessibility economics
Receptors, Tumor Necrosis Factor drug effects
Tumor Necrosis Factor-alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1618-7598
- Volume :
- 8 Suppl 2
- Database :
- MEDLINE
- Journal :
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publication Type :
- Academic Journal
- Accession number :
- 18157679
- Full Text :
- https://doi.org/10.1007/s10198-007-0086-x